Sequencing Radioligands Appears to be Safe, Viable Strategy for mCRPC
February 16th 2023Treatment with 177Lu-PSMA-617 results in similar survival benefit regardless of when it was administered after radium-223 in patients with metastatic castration-resistant prostate cancer, according to an expert from University Hospital of Münster in Germany.
Adding Daratumumab to RVd Improves MRD Negativity, PFS in Newly Diagnosed Myeloma
June 5th 2022Induction/consolidation daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed RVd alone when it came to minimal residual disease and progression-free survival in patients with newly diagnosed, transplant-eligible myeloma.
Naratuximab Emtansine/Rituximab Yields Promising Responses in DLBCL
December 13th 2021Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.
[vic]-Trastuzumab Duocarmazine Improved Survival For HER2-Positive Metastatic Breast Cancer
September 19th 2021Treatment [vic]-trastuzumab duocarmazine improved progression-free survival for patients with pretreated, metastatic HER2-positive breast cancer when compared with physician’s choice chemotherapy.
Helpful Markers for Immunotherapy Response May Lie With Mutations, irAEs
January 28th 2021Results from the 2020 World Conference on Lung Cancer Singapore demonstrated the feasibility of using STK11 mutations and immune-related adverse events as response predictors in patients with non–small cell lung cancer.
Novel AI Tool Helps Patients to Find, Understand Clinical Trials
January 15th 2021Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.